A Novel Target for Neuroblastoma Treatment |
Beckman Research Institute of City of Hope / Linda Malkas, Ph.D. |
Reach Grants |
2014 |
California |
Development of a Novel Mer Tyrosine Kinase Inhibitor for Treatment of ALL |
University of Colorado Denver / Doug Graham, MD, PhD |
Reach Grants |
2013 |
Colorado |
Novel Strategy for Reducing Radiation-Induced Morbidity and Treating Recurrent Medulloblasoma |
Massachusetts General Hospital / Rakesh Jain, PhD |
Reach Grants |
2013 |
Massachusetts |
LSD1 Inhibition to Treat T-cell Acute Lymphoblastic Leukemia/Lymphoma |
University of Virginia, School of Medicine / Michael Engel, MD/PhD |
Reach Grants |
2016 |
Virginia |
Immunoglobulin High-Throughput Sequencing for Refining Risk Stratification in Infant B-ALL |
University of Rochester / Carol Fries Simpson, MD |
Reach Grants |
2023 |
New York |
Identification of Aberrantly Methylated Differentially Expressed Genes to Distinguish High- vs. Low-Risk Retinoblastoma |
Children’s Hospital Los Angeles / Jesse Berry, MD |
Reach Grants |
2023 |
California |
Mechanistic and Therapeutic Development of ATM as a Tumor Cell Selective Target for Radiosensitization in H3K27M DMG |
The Regents of the University of Michigan / Meredith Morgan, PhD & Daniel Wahl, MD/PhD |
Reach Grants |
2022 |
Michigan |
IND-Enabling Studies for WNTinib, a Novel Selective Therapeutic for CTNNB1 Mutant Hepatoblastomas |
Icahn School of Medicine at Mount Sinai / Ernesto Guccione, PhD & Josep Llovet, MD & Arvin Dar, PhD |
Reach Grants |
2021 |
New York |
Phase I Study of Lentivirus Engineered Autologous AML Cells Expressing IL-12 in Children and Young Adults with Relapsed AML |
Children’s Hospital of Wisconsin - Milwaukee / Michael Burke, MD & Jeffrey Medin, MD/PhD |
Reach Grants |
2017 |
Wisconsin |
Optimizing TCRαβ+/CD19+-depleted haploidentical HSCT for ALL using donor-derived genome-edited CAR T cells |
Stanford University School of Medicine / Alice Bertaina, MD/PhD |
Reach Grants |
2019 |
California |